ReviewCancer science2007
Inhibition of angiogenesis in the treatment of non-small cell lung cancer.
Review in Cancer science, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 54 citations in OpenAlex.
- Metamorphic Effect of Angiogenic Switch in Tumor Development: Conundrum of Tumor Angiogenesis Toward Progression and Metastatic Potential.Biomedicines · 2023Review
- miRNA-1246 in extracellular vesicles secreted from metastatic tumor induces drug resistance in tumor endothelial cells.Scientific reports · 2021Article
- Limitations of Anti-Angiogenic Treatment of Tumors.Translational oncology · 2019Review
- Design, Synthesis and Biological Evaluation of Ligustrazine-Flavonoid Derivatives as Potential Anti-Tumor Agents.Molecules (Basel, Switzerland) · 2018Article
- Contribution of Tumor Endothelial Cells in Cancer Progression.International journal of molecular sciences · 2018Review
- Tumor angiogenesis--characteristics of tumor endothelial cells.International journal of clinical oncology · 2016Review
- Curcumin inhibited HGF-induced EMT and angiogenesis through regulating c-Met dependent PI3K/Akt/mTOR signaling pathways in lung cancer.Molecular therapy oncolytics · 2016Article
- Modulation, bioinformatic screening, and assessment of small molecular peptides targeting the vascular endothelial growth factor receptor.Cell biochemistry and biophysics · 2014Article
- Elevated soluble VEGF receptor sFlt-1 correlates with endothelial injury in IgA nephropathy.PloS one · 2014Article
- A subpopulation of circulating endothelial cells express CD109 and is enriched in the blood of cancer patients.PloS one · 2014Article
- Redundant kinase activation and resistance of EGFR-tyrosine kinase inhibitors.American journal of cancer research · 2014Review
- Polypharmacology: drug discovery for the future.Expert review of clinical pharmacology · 2013Review
- Phase I trial of axitinib combined with platinum doublets in patients with advanced non-small cell lung cancer and other solid tumours.British journal of cancer · 2012Article
- Biglycan is a specific marker and an autocrine angiogenic factor of tumour endothelial cells.British journal of cancer · 2012Article
- Sunitinib in combination with paclitaxel plus carboplatin in patients with advanced solid tumors: phase I study results.Cancer chemotherapy and pharmacology · 2011Article
- Global profiling and molecular characterization of alternative splicing events misregulated in lung cancer.Molecular and cellular biology · 2011Article
- New antiangiogenics in non-small cell lung cancer treatment: Vargatef™ (BIBF 1120) and beyond.Therapeutics and clinical risk management · 2011Article
- Role of pancreatic stellate cells in pancreatic cancer metastasis.The American journal of pathology · 2010Article
- Targeting angiogenesis with multitargeted tyrosine kinase inhibitors in the treatment of non-small cell lung cancer.The oncologist · 2010Review
- Serum vascular endothelial growth factor levels in patients with non-small cell lung cancer and its relations to the micrometastasis in peripheral blood.Journal of Huazhong University of Science and Technology. Medical sciences = Hua zhong ke ji da xue xue bao. Yi xue Ying De wen ban = Huazhong keji daxue xuebao. Yixue Yingdewen ban · 2009Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Angiogenesis and its role in the growth and development of metastases has become a topic of increasing importance. In non-small cell lung cancer (NSCLC), vascular endothelial growth factor (VEGF) plays an important role in angiogenesis, growth of the primary tumor, and development of metastases. In addition, elevated expression in tissue samples is a negative prognostic feature. For these reasons, VEGF is a worthy target for novel therapies. Recent clinical trials have shown that the anti-VEGF monoclonal antibody bevacizumab adds to the effect of chemotherapy in the metastatic setting. Hypertension and proteinuria are, as expected, commonly seen in this patient population, but the unexpected toxicity of life-threatening hemoptysis has also been observed. This makes careful patient selection especially important for this class of drugs. Our understanding of the VEGF pathway is increasing, as are the number of available targeted agents. In addition to the monoclonal antibody, bevacizumab, VEGF receptor tyrosine kinase inhibitors, multitargeted kinase inhibitors, and combination VEGF and epidermal growth factor receptor (EGFR) inhibition, are all being evaluated in NSCLC. Small phase I and II trials have suggested modest benefit when used alone; however, we now know that the anti-angiogenic therapies work best in combination with chemotherapy. The results of ongoing trials using these agents in combination with standard therapy will provide more insight into their potential benefit. As it is known that small tumors require angiogenesis to grow and metastasize, the use of anti-angiogenic therapies in the adjuvant setting may provide even greater benefit, and increase the potential cure rate in this population of patients. The results of well-designed phase III trials will be required to truly understand how to best use this class of targeted therapies in resectable and metastatic NSCLC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.